

EXECUTIVE SUMMARY

Vect-Horus is a French-based drug delivery biotechnology company founded in 2005 by Alexandre Tokay and Dr. Michel Khrestchatisky as a spin-off of the Institute for Neurophysiopathology of Marseille. The Company has developed an innovative vectorization platform VECTrans®, which includes a large range of proprietary vectors able to facilitate the transport of therapeutic and imaging agents to the brain and other tissues. Under a deeply experienced leadership team, Vect-Horus is developing a pipeline of products based on this technology and now has more than 10 pharma and biotech research collaborations, including three major licensing agreements with Novo Nordisk, Ionis and RadioMedix. It has raised about €40 million since its founding.

More than 10 R&D collaborations with world-class pharmaceutical companies, which are global specialists in their applications. These have already resulted in multiple licensing and option agreements

Two major licensing agreements signed in 2023



IONIS

A co-development & licensing agreement with RadioMedix for the diagnostic and therapy of glioblastoma and other cancers. The agent is currently in early Phase 1

Business Model

Vect-Horus' business model is based on partnering with pharma and biotech companies to vectorize their therapeutic molecules which have not demonstrated expected effects due to e.g. limited brain uptake. Following the proof-of concept studies, Vect-Horus' strategy is to out-license its vectors to the partner, which will further conduct the drug development process. The licensing agreements generate revenues that fund Vect-Horus' technology and its development programs.

Technology

Vectors	Peptides VHHs	Main challenges in treating CNS diseases & cancers ▪ The Blood-Brain-Barrier is a highly regulated and efficient protective barrier that separates the brain from the vascular system ▪ It prevents 98% of small-molecule and 100% of large-molecule drugs from penetrating the brain parenchyma. Drug transport into the brain is consequently hampered ▪ BBB crossing remains one of the toughest challenges for the treatment of CNS diseases VECTrans: A promising technology in drug delivery systems ▪ Vect-Horus has developed a unique drug delivery platform - VECTrans® ▪ This platform is built on peptide- and nanobody-based (VHH) patented vectors, conjugated to numerous classes of drugs (cargos), able to target various families of receptors, offering a highly versatile solution for on-demand targeted drug delivery ▪ Vect-Horus' fully patented innovative technology has demonstrated promising results in vitro and in vivo. One theragnostic agent, currently in early Phase 1 clinical trials, is co-developed with RadioMedix.
Target Receptors	LDLR TfR RAGE	
Cargos	Small molecules Peptides, oligos, proteins, mAbs, LNPs	
Indications	CNS diseases Cancers Muscular diseases	
Advanced Product	Phase 1 (Glioblastoma)	
Patents	8 families	

Mission

Vect-Horus' overarching objective is to become the leader in the field of targeted drug delivery. The Company is focusing on the development and optimization of its technology and its pipeline products, while accelerating its collaborations with pharma and biotech partners. Its licensing agreements are already generating revenues, and the earlier collaborations have the potential to develop into broader licensing deals which would generate future revenues.